Market Cap 135.42M
Revenue (ttm) 0.00
Net Income (ttm) -7.19M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 165,259
Avg Vol 1,744,598
Day's Range N/A - N/A
Shares Out 8.89M
Stochastic %K 31%
Beta 1.26
Analysts Strong Sell
Price Target $11.00

Company Profile

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic aller...

Industry: Biotechnology
Sector: Healthcare
Phone: 289 800 9600
Address:
100 Spy Court, Markham, Canada
Treb3k
Treb3k May. 15 at 9:24 PM
$EDSA sadly… i think next week is the week most of the OG longs here are cursing themselves saying why in the world did i not exit, and how did i let them get me again. they’ll probably end up raising at $5.. no new path, no new regulatory approach…
0 · Reply
Treb3k
Treb3k May. 15 at 9:17 PM
$EDSA so Point 72, Nantahala, and StonePipe all sold… Rubric stayed. Sirenia bought. plus someone converted some preferreds… anything we missed?
0 · Reply
EdV3
EdV3 May. 15 at 9:03 PM
0 · Reply
EdV3
EdV3 May. 15 at 9:02 PM
$EDSA The Q1 10Q and business update struck me as notoriously scant on details/updates, even for them. Not sure what to make of that.
1 · Reply
EdV3
EdV3 May. 15 at 8:48 PM
$EDSA Nantahala sold
0 · Reply
EdV3
EdV3 May. 15 at 8:46 PM
0 · Reply
Treb3k
Treb3k May. 15 at 8:35 PM
$EDSA point 72 confirmed out. @JoeDomiano. makes sense. they 10x’d in a month. looks like they sold to another fund https://edesabiotech.gcs-web.com/node/9711/html
0 · Reply
Treb3k
Treb3k May. 15 at 8:15 PM
$EDSA another 13G of another 7% holder - Rubric https://edesabiotech.gcs-web.com/node/9706/html
1 · Reply
Treb3k
Treb3k May. 15 at 7:10 PM
$EDSA or par at ATS
0 · Reply
Treb3k
Treb3k May. 15 at 7:09 PM
$EDSA or Par at ATS
0 · Reply
Latest News on EDSA
Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results

May 14, 2026, 4:30 PM EDT - 1 day ago

Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results


Edesa Biotech Inc trading halted, volatility trading pause

2026-04-28T14:26:55.000Z - 17 days ago

Edesa Biotech Inc trading halted, volatility trading pause


Edesa Biotech Inc trading resumes

2026-04-28T14:20:13.000Z - 17 days ago

Edesa Biotech Inc trading resumes


Edesa Biotech provides update on EB06 clinical study

2026-03-26T13:37:21.000Z - 7 weeks ago

Edesa Biotech provides update on EB06 clinical study


Edesa Biotech reports Q1 EPS (28c), consensus (45c)

2026-02-13T21:25:18.000Z - 3 months ago

Edesa Biotech reports Q1 EPS (28c), consensus (45c)


Edesa Biotech Reports Fiscal 1st Quarter 2026 Results

Feb 13, 2026, 4:20 PM EST - 3 months ago

Edesa Biotech Reports Fiscal 1st Quarter 2026 Results


Edesa Biotech Reports Fiscal Year 2025 Results

Dec 12, 2025, 4:20 PM EST - 5 months ago

Edesa Biotech Reports Fiscal Year 2025 Results


Edesa Biotech Announces Upcoming Conference Schedule

Oct 31, 2025, 4:30 PM EDT - 7 months ago

Edesa Biotech Announces Upcoming Conference Schedule


Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

Aug 8, 2025, 4:35 PM EDT - 10 months ago

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results


Edesa Biotech files $150M mixed securities shelf

2025-07-25T20:50:18.000Z - 10 months ago

Edesa Biotech files $150M mixed securities shelf


Edesa Biotech assumed with a Buy at H.C. Wainwright

2025-06-27T14:35:08.000Z - 11 months ago

Edesa Biotech assumed with a Buy at H.C. Wainwright


Edesa Biotech initiated with a Buy at Lucid Capital

2025-05-23T10:55:53.000Z - 1 year ago

Edesa Biotech initiated with a Buy at Lucid Capital


Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

May 14, 2025, 4:15 PM EDT - 1 year ago

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results


Edesa Biotech Announces Chief Financial Officer Transition

Apr 4, 2025, 4:15 PM EDT - 1 year ago

Edesa Biotech Announces Chief Financial Officer Transition


Edesa Biotech files to sell 7.81M common shares for holders

2025-03-04T21:36:26.000Z - 1 year ago

Edesa Biotech files to sell 7.81M common shares for holders


Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

Feb 14, 2025, 4:15 PM EST - 1 year ago

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results


Edesa Biotech Reports Fiscal Year 2024 Results

Dec 13, 2024, 4:30 PM EST - 1 year ago

Edesa Biotech Reports Fiscal Year 2024 Results


Edesa Biotech reports Q3 EPS (52c) vs (68c) last year

2024-08-09T20:21:43.000Z - 1 year ago

Edesa Biotech reports Q3 EPS (52c) vs (68c) last year


Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

Aug 9, 2024, 4:20 PM EDT - 1 year ago

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results


Edesa Biotech reports Q2 EPS (58C), consensus (69C)

2024-05-10T20:18:59.000Z - 2 years ago

Edesa Biotech reports Q2 EPS (58C), consensus (69C)


Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

May 10, 2024, 4:15 PM EDT - 2 years ago

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results


Edesa Biotech to Participate in Upcoming Investor Conferences

Apr 2, 2024, 9:00 AM EDT - 2 years ago

Edesa Biotech to Participate in Upcoming Investor Conferences


Edesa Biotech to Participate in Upcoming Dermatology Meetings

Mar 4, 2024, 4:30 PM EST - 2 years ago

Edesa Biotech to Participate in Upcoming Dermatology Meetings


Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

Feb 9, 2024, 4:15 PM EST - 2 years ago

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results


Edesa Biotech Reports Fiscal Year 2023 Results

Dec 15, 2023, 4:10 PM EST - 2 years ago

Edesa Biotech Reports Fiscal Year 2023 Results


Edesa Biotech to Present at Dermatology Drug Development Summit

Oct 26, 2023, 4:05 PM EDT - 2 years ago

Edesa Biotech to Present at Dermatology Drug Development Summit


Edesa Biotech Announces One-for-Seven Reverse Share Split

Oct 10, 2023, 9:00 AM EDT - 2 years ago

Edesa Biotech Announces One-for-Seven Reverse Share Split


Edesa Biotech Reports Fiscal Third Quarter 2023 Results

Aug 9, 2023, 4:15 PM EDT - 3 years ago

Edesa Biotech Reports Fiscal Third Quarter 2023 Results


Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

Jun 27, 2023, 8:15 AM EDT - 3 years ago

Edesa Biotech Appoints Biotech Deal Veteran to CFO Role


Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name

Jun 15, 2023, 8:00 AM EDT - 3 years ago

Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name


Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

May 11, 2023, 4:30 PM EDT - 3 years ago

Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results


Edesa Biotech to Participate in Swiss Biotech Day

Apr 20, 2023, 8:30 AM EDT - 3 years ago

Edesa Biotech to Participate in Swiss Biotech Day


Edesa Biotech Reports Fiscal 1st Quarter 2023 Results

Feb 10, 2023, 9:00 AM EST - 3 years ago

Edesa Biotech Reports Fiscal 1st Quarter 2023 Results


FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate

Dec 20, 2022, 8:30 AM EST - 3 years ago

FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate


Edesa Biotech Reports Fiscal Year 2022 Results

Dec 16, 2022, 9:00 AM EST - 3 years ago

Edesa Biotech Reports Fiscal Year 2022 Results


Treb3k
Treb3k May. 15 at 9:24 PM
$EDSA sadly… i think next week is the week most of the OG longs here are cursing themselves saying why in the world did i not exit, and how did i let them get me again. they’ll probably end up raising at $5.. no new path, no new regulatory approach…
0 · Reply
Treb3k
Treb3k May. 15 at 9:17 PM
$EDSA so Point 72, Nantahala, and StonePipe all sold… Rubric stayed. Sirenia bought. plus someone converted some preferreds… anything we missed?
0 · Reply
EdV3
EdV3 May. 15 at 9:03 PM
0 · Reply
EdV3
EdV3 May. 15 at 9:02 PM
$EDSA The Q1 10Q and business update struck me as notoriously scant on details/updates, even for them. Not sure what to make of that.
1 · Reply
EdV3
EdV3 May. 15 at 8:48 PM
$EDSA Nantahala sold
0 · Reply
EdV3
EdV3 May. 15 at 8:46 PM
0 · Reply
Treb3k
Treb3k May. 15 at 8:35 PM
$EDSA point 72 confirmed out. @JoeDomiano. makes sense. they 10x’d in a month. looks like they sold to another fund https://edesabiotech.gcs-web.com/node/9711/html
0 · Reply
Treb3k
Treb3k May. 15 at 8:15 PM
$EDSA another 13G of another 7% holder - Rubric https://edesabiotech.gcs-web.com/node/9706/html
1 · Reply
Treb3k
Treb3k May. 15 at 7:10 PM
$EDSA or par at ATS
0 · Reply
Treb3k
Treb3k May. 15 at 7:09 PM
$EDSA or Par at ATS
0 · Reply
Treb3k
Treb3k May. 15 at 7:08 PM
$EDSA Par at ATS
0 · Reply
JoeDomiano
JoeDomiano May. 15 at 6:53 PM
$EDSA I can't freaking wait for tonight. Par is The Man.
0 · Reply
mapleleafdave
mapleleafdave May. 15 at 5:15 PM
$EDSA Platac, is that you? 😂
2 · Reply
bachsong
bachsong May. 15 at 5:01 PM
$EDSA The "muted" reaction you noted earlier ($13.03 – $13.50 range) is likely because the high-value oral presentation has not happened yet. EDSA Oral Presentation is NOT UNTIL 6:10 PM: The Opening Showcase (Dr. Nijhawan’s time). Expect This Evening The impact will likely occur after-hours or in the Monday morning pre-market (especially given the Monday morning earnings report). Key watch: 6:10 PM: Dr. Nijhawan’s Opening Showcase begins. 6:30 PM+: Potential upload of the presentation slide deck to the Edesa website. Saturday Morning: More networking and "Showcase One: Breakthroughs in Critical Care" which will likely draw more eyes to Edesa’s ARDS data. Strategic Insight The market "drift" today followed by the bounce back to $13.50 suggests that the institutional floor is holding in anticipation of this 6:10 PM presentation. Large investors like Sirenia Capital likely already have the data, but the "retail momentum" usually follows the 6:00 PM news cycle and the formal slide deck release.
1 · Reply
EdV3
EdV3 May. 15 at 4:44 PM
$EDSA Would this invalidate their submission?
1 · Reply
Treb3k
Treb3k May. 15 at 4:33 PM
$EDSA PreventARDS reads like it was created for Edesa. they absolutely must be THE top candidate here. And BARDA already has insights into their clinical performance. The PreventARDS materials also point to a real late-stage program, not just a small grant. The RFI/sources-sought package says BARDA wanted input for host-directed therapeutics to prevent progression to ARDS in hospitalized viral-respiratory-infection patients, with emphasis on late-stage clinical development and long-term partnerships with multiple contractors. It also says the draft RPP would require a Phase 3 development plan, Phase 2 efficacy support, and preferably a product already in Phase 3.
3 · Reply
EdV3
EdV3 May. 15 at 4:32 PM
$EDSA You mean other than actually providing a full time committment, right :)
1 · Reply
Treb3k
Treb3k May. 15 at 4:23 PM
$EDSA there is a flywheel effect that could happen here. if they announce something or see institutional buying which drives the share price above $25, they have almost $10M in potential cash proceeds available, which if excersized, will further drive up the share price from further extending their runway. if they announce Canadian SIF or BARDA awarded them on the RFI/SSN for Host Directed Therapeutics for the Prevention of Progression to ARDS. They could see buying which in turn allows them to get further warrant proceeds to fund EB06, then driving further buying from reduced risk of dilution. all of that would happen without increasing the total diluted number.
0 · Reply
Treb3k
Treb3k May. 15 at 4:14 PM
$EDSA - have to say, Par has regularly done all he could as a CEO to show his support and buy in on the company. https://edesabiotech.gcs-web.com/node/9701/html
0 · Reply
I_Hate_Stock_Twits
I_Hate_Stock_Twits May. 15 at 4:13 PM
$EDSA going concern statement and no raise...sigh
0 · Reply
EdV3
EdV3 May. 15 at 3:37 PM
$EDSA not selling a single share under the atm is rather gross negligence or incredibly bullish lol....take your pick with these guys
1 · Reply
Treb3k
Treb3k May. 15 at 3:26 PM
$EDSA S-S-R! S-S-R! the recovery has been consistent every time
0 · Reply